Abstract
Background A 73-year-old Asian man with a history of lipidemia, hypertension and myocardial infarction presented with dizziness, decreased appetite, weight loss, nonproductive cough and fatigue. His physical performance status was good, and physical examination was unremarkable except for lower-extremity pitting edema.
Investigations Physical examination, brain MRI, CT scans of the chest, abdomen and pelvis, bone scan, CT scan-guided biopsy, hematoxylin and eosin staining, EGFR mutational analysis, and chest X-ray.
Diagnosis Stage IV non-small-cell lung cancer with brain metastasis.
Management Oral erlotinib 150 mg daily for 10 months and ongoing, and whole-brain irradiation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Pao W et al. (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non–small cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556–2568
Janne P et al. (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23: 3227–3234
Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139
Paez JG et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500
Pao W et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13307–13311
Miller VA et al. (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103–1109
Shepherd FA et al. (2005) Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med 353: 123–132
Tsao MS et al. (2005) Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 353: 133–144
Schiller J et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98
Sandler A et al. (2006) Paclitaxel with or without bevacizumab for metastatic non-small-cell lung cancer. N Engl J Med 355: 2542–2550
Ceresoli GL et al. (2004) Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15: 1042–1047
Hotta K et al. (2004) Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46: 255–261
Shimato S et al. (2006) EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol 8: 137–144
Jackman D et al. (2006) Response and resistance in a non–small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24: 4517–4520
Pao W et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73
Balak MN et al. (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor–mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494–6501
Choong NW et al. (2006) Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation. Nat Clin Pract Oncol 3: 50–57
Das AK et al. (2006) Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 66: 9601–9608
Giaccone G et al. (2006) Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 12: 6049–6055
Acknowledgements
We thank D Baer for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Pan, M., Santamaria, M. & Wollman, D. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nat Rev Clin Oncol 4, 603–607 (2007). https://doi.org/10.1038/ncponc0931
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0931
This article is cited by
-
Oral Targeted Therapies and Central Nervous System (CNS) Metastases
CNS Drugs (2015)
-
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292
Clinical & Experimental Metastasis (2011)